Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

sandoz a/s* - metforminum hýdróklóríð - filmuhúðuð tafla - 500 mg

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

teva b.v.* - metforminum hýdróklóríð - filmuhúðuð tafla - 500 mg

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

eql pharma ab - metforminum hýdróklóríð - filmuhúðuð tafla - 500 mg

Evrópusambandið - íslenska - EMA (European Medicines Agency)

accord healthcare s.l.u. - metformin hydrochloride, vildagliptin - sykursýki, tegund 2 - lyf notuð við sykursýki - vildagliptin/metformin hydrochloride accord is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:- in patients who are inadequately controlled with metformin hydrochloride alone. - in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. - in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 og 5. 1 fyrir tiltæk gögn um mismunandi samsetningar).

Evrópusambandið - íslenska - EMA (European Medicines Agency)

accord healthcare s.l.u. - metformin hydrochloride, sitagliptin hydrochloride monohydrate - sykursýki, tegund 2 - lyf notuð við sykursýki - for adult patients with type 2 diabetes mellitus:it is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. it is indicated in combination with a sulphonylurea (i. , þrefaldur samsetning meðferð) sem viðbót til að fæði og æfing í sjúklingar ekki nægilega stjórn á eigin hámarks þolað skammt af sjúklingar og sulphonylurea. it is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparγ agonist. it is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

krka, d.d., novo mesto - sitagliptinum inn; metforminum hýdróklóríð - filmuhúðuð tafla - 50 mg/1000 mg

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

krka, d.d., novo mesto - sitagliptinum inn; metforminum hýdróklóríð - filmuhúðuð tafla - 50 mg/850 mg

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

medical valley invest ab - sitagliptinum hýdróklóríð; metforminum hýdróklóríð - filmuhúðuð tafla - 50mg/850 mg

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

krka d.d. novo mesto* - vildagliptinum inn; metforminum hýdróklóríð - filmuhúðuð tafla - 50 mg/850 mg

Evrópusambandið - íslenska - EMA (European Medicines Agency)

mylan ireland limited - sitagliptin hydrochloride monohydrate, metformin hydrochloride - sykursýki, tegund 2 - lyf notuð við sykursýki - for adult patients with type 2 diabetes mellitus:sitagliptin/metformin hydrochloride mylan is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. sitagliptin/metformin hydrochloride mylan is indicated in combination with a sulphonylurea (i. , þrefaldur samsetning meðferð) sem viðbót til að fæði og æfing í sjúklingar ekki nægilega stjórn á eigin hámarks þolað skammt af sjúklingar og sulphonylurea. sitagliptin/metformin hydrochloride mylan is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparg) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparg agonist. sitagliptin/metformin hydrochloride mylan is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.